All In Biotech

Drug Trial Radar · NCT05428969

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

181

Planned (sponsor's estimate)

Start

Jun 2, 2022

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Faron Pharmaceuticals LtdIndustry
Sponsor type
Industry
First posted
Jun 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.

Conditions

  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndromes
  • Relapsed/Refractory AML

Interventions

  • BexmarilimabDrug

    Intravenous

  • AzacitidineDrug

    As per label, subcutaneous

  • VenetoclaxDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reporting of incidence and frequency of dose limiting toxicities (DLTs).Time frame: From study start to end of Cycle 1 (each cycle is 28 days)
  2. Frequency and severity based on NCI-CTCAE grading of treatment emergent AEs and serious adverse events (SAE).Time frame: From study start to 30 days after end of treatment (EOT)
  3. Complete response (CR) rate for MDS and CMML-2.Time frame: From study start to 30 days after EOT
  4. Overall response rate (ORR) for MDS and CMML failure to prior HMA.Time frame: From study start to 30 days after EOT
  5. Complete remission with incomplete blood recovery (CRi) for r/r AML.Time frame: From study start to 30 days after EOT
  6. Minimal residual disease (MRD) status for newly diagnosed AML.Time frame: From study start to 30 days after EOT

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • Yale Cancer Center

    New Haven, Connecticut

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • Helsinki University Hospital

    Helsinki, Finland

  • Kuopio University Hospital

    Kuopio, Finland

  • Oulu University Hospital

    Oulu, Finland

  • Tampere University Hospital

    Tampere, Finland

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Royal Cornwall Hospitals NHS Trust

    Truro, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.